Next in sealants, glues, hemostats…and why?

From July 2016 published Report #S290.

The need for surgical sealants, glues, and hemostats is directly related to the clinical caseload and procedure volumes, while product choice is dependent upon the surgeon’s training and experience with the products, the particular situation, and product availability. Availability is influenced by several factors. For example, must the product be prepared before use, or is it ready to use off the shelf? Is it refrigerated, requiring warming prior to use, or is the product able to be stored at room temperature? Availability also depends on whether the hospital or healthcare facility will stock the product, which in turn depends on the product’s cost and whether it fits into the facility’s budget and formulary. Sealants, glues and hemostats are used about 25% of the time in many (but not all) procedures, since sutures remain the most familiar and least expensive products for wound closure. However, the products addressed in this report could well find use in over 100 million procedures globally.

Here are six key trends we see in the global market next in surgical sealants, glues, hemostats:

  1. Aggressive development of products (including by universities, startups, established competitors), regulatory approvals, and new product introductions continues in the U.S., Europe, and Asia/Pacific (mostly Japan, Korea) to satisfy the growing volume of surgical procedures globally.
  2. Rapid adoption of sealants, glues, and hemostats in China will drive much of the global market for these products, but other nations in the region are also big consumers, with more of the potential caseload already tapped than the rising economic China giant. Japan is a big developer and user of wound product consumer. Per capital demand is also higher in some countries like Japan.
  3. Flattening markets in the U.S. and Europe (where home-based manufacturers are looking more at emerging markets), with Europe in particular focused intently on lowering healthcare costs.
  4. The M&A, and deal-making that has taken place over the past few years (Bristol-Myers Squibb, The Medicines Company, Cohera Medical, Medafor, CR Bard, Tenaxis, Mallinckrodt, Xcede Technologies, etc.) will continue as market penetration turns to consolidation.
  5. Growing development on two fronts: (1) clinical specialty and/or application specific product formulation, and (2) all purpose products that provide faster sealing, hemostasis, or closure for general wound applications for internal and external use.
  6. Bioglues already hold the lead in global medical glue sales, and more are being developed, but there are also numerous biologically-inspired, though not -derived, glues in the starting blocks that will displace bioglue shares. Nanotech also has its tiny fingers in this pie, as well.

See Report #S290, “Worldwide Sealants, Glues, and Hemostats Markets, 2015-2022”.